Entera Bio Ltd. (ENTX)
NASDAQ: ENTX · Real-Time Price · USD
1.250
+0.020 (1.63%)
Mar 6, 2026, 4:00 PM EST - Market closed
Entera Bio Employees
As of December 31, 2024, Entera Bio had 20 total employees, including 20 full-time and 2 part-time employees. The number of employees increased by 2 or 11.11% compared to the previous year.
Employees
20
Change (1Y)
2
Growth (1Y)
11.11%
Revenue / Employee
$5,636
Profits / Employee
-$490,045
Market Cap
57.32M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| MindWalk Holdings | 102 |
| ImmuCell | 84 |
| LeonaBio | 26 |
| Plus Therapeutics | 21 |
| Rallybio | 15 |
| Instil Bio | 14 |
| Spruce Biosciences | 9 |
| Grace Therapeutics | 6 |
ENTX News
- 3 days ago - Entera Bio Submits Streamlined Phase 3 Protocol to Initiate Registrational Program for EB613 in Postmenopausal Women with Osteoporosis - GlobeNewsWire
- 24 days ago - Entera Bio Announces Open Market Purchases of Company Stock by Board Members - GlobeNewsWire
- 26 days ago - Entera Bio Appoints Former Pfizer Executive Geno J. Germano as Chairman of the Board Ahead of Key Milestones - GlobeNewsWire
- 2 months ago - Entera Bio Congratulates the FNIH-ASBMR-SABRE Team on FDA's Qualification of Total Hip BMD as Regulatory Endpoint: Huge Win for Osteoporosis Innovation - GlobeNewsWire
- 2 months ago - Entera Bio Announces New Data Supporting Further Development of a Proprietary First-in-Class Oral, Long-Acting PTH Tablet for Patients with Hypoparathyroidism (EB612 Program) - GlobeNewsWire
- 3 months ago - Entera Bio to Participate in the 8th Annual Evercore ISI Healthcare Conference - GlobeNewsWire
- 4 months ago - Entera Bio Presents Positive New Clinical Data from EB613 Phase 2 Trial Demonstrating Significant Bone Density Improvements in Early Postmenopausal Women - GlobeNewsWire
- 5 months ago - Entera Bio to Present New Clinical Data from Phase 2 Trial of EB613 at the 2025 North American Menopause Society (NAMS) Annual Meeting - GlobeNewsWire